Vanazzi, Anna
https://orcid.org/0000-0002-2977-4208
Mayo Clinic
Division of Clinical Haemato-Oncology, Milano, Italy;
Citations 1
PILLAR-2: A randomized, double-blind, placebo-controlled, phase III study of adjuvant everolimus (EVE) in patients (pts) with poor-risk diffuse large B-cell lymphoma (DLBCL).
Tobinai, Kensei , Lin, Tongyu , Vanazzi, Anna , Hino, Masayuki , Shi, Yuankai , Mayer, Jiřı́ , Bermúdez, Carlos , Zhu, Jun , Bouabdallah, Kamal , Kattan, Joseph , Wu, Cassandra, Fan, Jenna, Louveau, Anne-Laure, Voi, Maurizio, Cavalli, Franco , Witzig, Thomas E. , Rigacci, Luigi , Ikeda, Takashi , Costa, Luciano J. , Belada, David
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 7506-7506
